ANRO DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's IPO and subsequent securities transactions [1][2]. Group 1: Class Action Details - Investors who purchased Alto securities during the class period from February 2, 2024, to October 22, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit alleges that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, having recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].